Published research: 19 November 2026 | Journal: Forensic Toxicology | Study type: original research
- What did the researchers investigate?
- The findings in numbers
- Why oral fluid is useful in emerging-drug surveillance
- What does this mean for forensic laboratories?
- Important limitations
- Why this matters
- How should a laboratory interpret a new analogue detection?
- Practical Interpretation Checklist
- Frequently Asked Questions
- References
A new Brazilian study has identified two ketamine-related compounds, deschloroketamine (DCK) and 2-fluoro-deschloroketamine (2-FDCK), in oral fluid collected at recreational events. The result is an important analytical observation, but it is not evidence of widespread use. In fact, both analogues were found in only four unique specimens in the selected sample set.
Research at a Glance
First report of deschloroketamine (DCK) and 2-fluoro-deschloroketamine (2-FDCK) in oral fluid samples from recreational settings in Brazil
Study summary
408 previously screening-positive oral-fluid specimens were investigated; 198 had at least one confirmed target analyte and four unique samples contained DCK and/or 2-FDCK.
Critical appraisal
- Limitations
- Selected screening-positive specimens and low numbers of analogue-positive samples; findings cannot estimate population prevalence, exposure dose or impairment.
- Implications
- Drug-monitoring laboratories may evaluate whether validated panels adequately distinguish emerging ketamine analogues.
Key Takeaways
Research findings must be evaluated against the study design and validation limits.
- DCK was detected in four selected oral-fluid specimens; two of these also contained 2-FDCK.
- The study examined 408 initially screen-positive samples, not a representative population sample.
- Low-level detection supports targeted surveillance, not a claim of widespread use.
- Presence of an analyte is not proof of dose, impairment, timing or consent.
What did the researchers investigate?
Rodrigues and colleagues examined oral-fluid samples collected at festivals and parties in Brazil between October 2023 and May 2025. Their work focused on ketamine, the metabolite norketamine, 6-hydroxynorketamine and the analogues DCK and 2-FDCK. The study was published on 19 November 2026 in Forensic Toxicology, DOI 10.1007/s11419-026-00791-2.
The findings in numbers
- Researchers examined 408 oral-fluid samples with a positive initial screening result.
- 198 samples were confirmed positive and quantified for at least one of the study analytes.
- DCK was found in four samples; 2-FDCK in two.
- The two 2-FDCK-positive specimens were also DCK-positive. Thus, four unique samples contained at least one of these two analogues.
- The measured analogue concentrations were near the method’s lower limit of quantification, approximately 10–15 ng/mL.
That last point matters. The four analogue-positive specimens represent 1.0% of the 408 screening-positive subset, not 1.0% of the general Brazilian population or of everyone attending recreational events. Participants were not recruited as a population-representative sample.
Why oral fluid is useful in emerging-drug surveillance
Oral-fluid collection is relatively quick, non-invasive and suited to event-based monitoring. It can recover parent compounds that may be harder to characterize through urinary metabolites, particularly when new psychoactive substances lack established metabolic reference data. Yet this matrix also has limitations: timing of collection, possible recent oral contamination and the shorter detection window compared with some other sample types can complicate interpretation.
What does this mean for forensic laboratories?
The result is a reason for laboratories developing new psychoactive substance panels to review the analytical scope of their methods. Structural similarity does not guarantee that a routine ketamine assay will identify and distinguish DCK and 2-FDCK. Any expansion of a confirmatory method needs suitable reference materials, selectivity assessment, detection and quantification limits, quality controls, and validation appropriate to the matrix and intended use.
Crucially, a confirmed presence result should not be translated into an impairment conclusion. Oral-fluid concentration, by itself, does not establish the administered dose, timing, pharmacological effect or whether a substance was deliberately taken.
Important limitations
- Only four unique analogue-positive specimens were observed.
- All analogue concentrations were close to the analytical quantification threshold.
- Neither suspected drug products nor seized substances were analyzed to determine whether the analogues were adulterants, manufacturing impurities or separately consumed.
- Sampling occurred in specific recreational settings and does not provide a national prevalence estimate.
- Authors noted uncertainty associated with specimen storage duration, self-report and matrix-specific detection windows.
Why this matters
The strongest conclusion is modest but useful: two emerging ketamine analogues have now been analytically confirmed in authentic oral-fluid specimens from recreational settings. Larger prospective studies and continued method development are needed to learn how commonly these compounds occur, whether exposure patterns are changing and which testing approaches are most informative.
For broader context, see Simply Forensic’s guides to forensic drug chemistry and drug-facilitated sexual assault. The latter is a general background resource; the Brazilian study did not investigate sexual assault.
How should a laboratory interpret a new analogue detection?
The first question is analytical: does the laboratory have evidence that the observed signal belongs to the named compound rather than another substance with a similar response? A casework result needs a method that distinguishes relevant interferences and an interpretation that stays inside the validated scope. A compound absent from the targeted panel may remain unreported even when ketamine itself is routinely measured. Conversely, a research method developed for surveillance should not be treated as an accredited casework method without its own validation.
For the reader, the difference between the number of positive samples and the number of distinct affected specimens is equally important. DCK and 2-FDCK were not found in six different specimens. Two specimens contained both analogues. The appropriate public-health message is the need to watch for emerging compounds, not an unsupported claim about rising prevalence.
Practical Interpretation Checklist
Laboratory Interpretation Checklist
Educational self-review only: checking an item does not establish laboratory QC acceptance.
Frequently Asked Questions
Frequently Asked Questions
What are DCK and 2-FDCK?
They are ketamine-related compounds. Their structural similarities create a need for selective identification methods.
Were six separate samples positive?
No. DCK appeared in four samples and 2-FDCK in two of those same four.
Does an oral-fluid positive prove impairment?
No. It confirms analyte presence under the validated analytical procedure; impairment is a separate question.
References
References & Sources
Show referencesHide references
- Rodrigues LC, Luiz ECS, Borbi LS, et al. First report of deschloroketamine (DCK) and 2-fluoro-deschloroketamine (2-FDCK) in oral fluid samples from recreational settings in Brazil. Forensic Toxicology. 2026. Source



